# Ustekinumab for the Treatment of Giant Cell Arteritis

> **NCT02955147** · PHASE1,PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 13 (actual)

## Conditions studied

- Giant Cell Arteritis
- Temporal Arteritis
- Horton's Disease

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02955147
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-09-19
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Inefficacy
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955147, "Ustekinumab for the Treatment of Giant Cell Arteritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02955147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*